AMRX vs OGN · P/E 44, rev $2.79B vs P/E 3.4, rev $6.40B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the AMRX and OGN stock pages for the full models.
Not investment advice.